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ABSTRACT
Objective: To determine the extent of substandard
and falsified medicines in the UK.
Design: A retrospective review of drug alerts and
company-led recalls.
Setting: The Medicines and Healthcare Products
Regulatory Agency (MHRA) website search for drug
alerts issued between 2001 and 2011.
Eligibility criteria: Drug alerts related to quality
defect in medicinal products.
Main outcome measure: Relevant data about
defective medicines reported in drug alerts and
company-led recalls, including description of the
defect, type of formulation, year of the alert and
category of the alert.
Results: There were 280 substandard medicines of
which 222 were recalled. The two most frequent
problems were contamination (74 incidents) and issues
related to packaging (98 incidents). Formulations for
parenteral administration (117 incidents) were the
formulation most frequently affected. There were
11 falsified medicines, as defined by the MHRA,
reported over the 11-year period. The number of
defective medicines reported by the MHRA increased
10-fold from 5 in 2001 to 50 in 2011.
Conclusions: Substandard medicines are a significant
problem in the UK. It is uncertain whether the
increasing number of reports relates to improved
detection or an increase in the number of substandard
medicines.
INTRODUCTION
Falsiﬁed and substandard medicines are a
signiﬁcant problem throughout the world.1–4
Most of the evidence for this has been
reported from Africa and Asia in low and
lower middle income countries.1–3 Little evi-
dence, however, is available for European
and Northern American countries, as no
individual studies about the problem have
been published in high-income countries.
According to European commission data,
the incidence of this problem in the
European supply chain is growing by 10–20%
annually.5 6
In the UK, the Medicines and Healthcare
products Regulatory Agency (MHRA) has
the responsibility of safeguarding the public
from the risk of these drugs. The MHRA’s
Defective Medicines Report Centre (DMRC)
is the department responsible for receiving
and assessing reports about suspected defect-
ive drugs. Drug alerts are issued by the
DMRC to the manufacturer, wholesalers and
healthcare providers, in cases where a defect-
ive medicine is shown to compromise
patients’ safety.7
The aims of this study were to describe the
number of drug alerts issued by the MHRA
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and to determine the extent of substandard and falsiﬁed
medicines in the UK.
METHODS
The DMRC deﬁnes a defective drug as a “drug which
proves to be harmful under normal conditions of use,
lacking in therapeutic efﬁcacy and/or the qualitative
and quantitative composition of a drug is not as
declared. A drug can also be defective if the controls on
a drug and/or on the ingredients and the controls at an
intermediate stage of the manufacturing process have
not been carried out or if some other requirement or
obligation relating to the grant of the manufacturing
authorisation has not been fulﬁlled.”8
There is currently no agreed international deﬁnition
of a falsiﬁed medical product. The 2011 WHO deﬁn-
ition of substandard/spurious/falsely labelled/falsiﬁed/
counterfeit medical products does not differentiate
between different types of compromised medicines that
need distinct regulatory actions.9 Attaran et al4 have pro-
posed a clearer deﬁnition, differentiating between falsi-
ﬁed and substandard medicines in relation to if a
medicine is a public health crime, and therefore an
intentional wrong doing, or if there has been a regula-
tory failure and no intentional wrong has taken place.
No speciﬁc deﬁnition exists within English law and the
MHRA adopts the deﬁnition contained within the
European Falsiﬁed Medicines Directive. They look for
clear evidence that there was an intention to deceive a
consumer, patient, healthcare professional and/or oper-
ator within the supply chain, into believing that the
medical product being manufactured offered or sup-
plied was the genuine article when in fact it was not.10
In this paper, we deﬁne medicines that failed to pass the
quality measurements and standards set for them as sub-
standard medicines. On the contrary, falsiﬁed medicines
are those which do not meet the quality speciﬁcations of
regulatory authority with deliberate intent.
A search for drug alerts related to defective medicinal
products was carried out. This was performed through
the ofﬁcial MHRA website using the section allocated
for drug alerts. The ﬁrst drug alert reported on the
MHRA website was in the year 2001; thus, all drug alerts
issued between 2001 and 2011 were included.
Manufacturers can also voluntarily recall their defective
products without the need for a drug alert to be issued
by the MHRA in cases where defective medicines have
left manufacturing sites but have had limited distribu-
tion in the supply chain. The MHRA started posting
these recalls under its company-led recall section in
2011; hence, all these recalls were included. The result-
ing alerts and recalls were compiled and exclusion cri-
teria included the following: drug alert replaced by
another updated one, drug alert duplication, alert about
clariﬁcation of medicine information, medical device
alert and alert about medicines lacking efﬁcacy or
having signiﬁcant toxicity.
The following data were extracted from these alerts:
name, strength and dosage form; year of the alert;
number of affected batches; nature of the defect; class
of drug alert and action to be taken about defective
medicine. Substandard medicines were then subdivided
according to the type of the defect into the following:
▸ Contamination: Defect related to microbial contamina-
tions and issues related to sterility as well as chemical
and particulate (ie, impurities) contamination.
▸ Minor packaging defect: Defects that occur in relation
to the printing of packaging materials, for instance,
printed box errors that involve a missing or incorrect
expiry date or batch number of a medicine. This also
includes any errors in the patients’ information leaf-
lets or summary of product characteristic.
▸ Major packaging defects: A defect that involves packing
a medicine in a wrong box or carton or printing
errors that involve missing or incorrect name or
strength of a medicine.
▸ Delivery: A technical or physical defect such as broken
capsules or leaking containers.
▸ Stability failure: Defect results from the failure of the
medicine to remain within the established standards
throughout the expiration period, for example, low
assay of the active ingredient prior to a product expiry.
▸ Potency: Failure of the medicine to evoke the desired
effect within the stated strength.
▸ Defect in active ingredient: Defect results from the active
ingredient being inadequate or excessive in the
formulation.
▸ Other defects: Other deviations concerning non-
compliance with good manufacturing practice at
manufacturing site.
The total number of alerts was obtained and each
individual medicine reported in these alerts was then
extracted. Defective medicines were then classiﬁed
according to the WHO Anatomical Therapeutic
Chemical Classiﬁcation System. This system uses ﬁve
levels to classify medicines and the ﬁrst two levels were
used in this section. The ﬁrst level classiﬁes medicine
according to the system or organ on which the medicine
acts; whereas, the second level classiﬁes medicine
according to its main therapeutic group.11
Company-led recalls are initiated by manufacturers
after consultation with the MHRA, without giving the
recall any degree of urgency. Drug alerts, by contrast,
are issued by the MHRA and have four possible classiﬁ-
cations based on the level of the risk.8 These classes are
as follows:
▸ Class 1 drug alert: The defect in a medicine is life-
threatening and poses a serious risk to patient health.
▸ Class 2 drug alert: The defect in a medicine is not life-
threatening but can still be harmful to patients.
▸ Class 3 drug alert: The defect in a medicine is unlikely
to be hazardous to patients, but an alert is issued,
due to problems related to non-compliance with
good manufacturing practices or marketing
authorisations.
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▸ Class 4 drug alert: The least critical alert; advises
“caution in use”.
Classes 1, 2 and 3 drug alerts require recalls of
affected batches, whereas class 4 alerts do not require
recalls but require caution in dealing with defective
medicines.8
Three types of compromised medicine can be recog-
nised in the alerts; namely: falsiﬁed, substandard and
medicines withdrawn because of safety or toxicity con-
cerns. The decision of which medicines were falsiﬁed
was made from the MHRA classiﬁcation.12 Only medi-
cines where it was made clear in the recall that the
batch was regarded by the MHRA as counterfeit/falsi-
ﬁed were given this label. No data were available to the
authors to further analyse if the error was intentional or
non-intentional. All alerts that were not included in the
MHRAs’ speciﬁc falsiﬁed medical products list were
therefore classiﬁed as substandard medicines.
RESULTS
Incident trends
There were a total of 244 drug alerts issued by the
MHRA. After applying the aforementioned exclusion cri-
teria, 30 were excluded. In turn, 214 were deemed suit-
able for inclusion (ﬁgure 1). Analysis showed that these
alerts reported 269 medicines, each of which repre-
sented an individual incident. The majority of these
alerts were issued for individual medicines. However,
some were issued for up to 14 medicines.
Since MHRA started reporting drug alerts online in
2001, there has been a gradual increase in the rate of
drug alerts related to defective medicinal products. The
number of drug alerts increased from 5 in 2001 to 31 in
2011. The number of defective medicines reported by
these alerts was ﬁve in 2001. This ﬁgure increased
10-fold by 2011, to a total of 50 (ﬁgure 2).
Defective medicines recalled by the MHRA under classes
1–4 drug alerts
Seventeen medicines were recalled under class 1 drug
alerts. The highest number of alerts was issued for con-
tamination reasons. The most frequent formulations
reported were formulations for parenteral administra-
tion, which accounted for seven cases. The median time,
when stated, taken by the MHRA to identify these medi-
cines as defective, from medicines being available on the
market, to issuing alerts was 64 days (range 13–242 days).
The length of this time period is critical, as the chance of
adverse events increases as the time of exposure
increases. Details of these alerts are shown in table 1.
Under class 2 alert, 161 medicines were recalled. The
main issues were related to contamination and minor
packaging defects. There were also 87 medicines
recalled under class 3 or 4 alerts (see online
supplementary table S1).
Defective medicines recalled by manufacturers
(company-led recalls)
It was observed that 19 company-led recalls were issued by
the manufacturers in 2011. One recall was excluded after
applying the exclusion criteria. Thus, 18 company-led
recalls were included and these were issued for a total of
22 defective medicines (ﬁgure 1).
Defective medicines, classified by type of defect
The incidents of defective medicines reported by the
MHRA (269) were compiled with those reported by the
manufacturers (22), which resulted in 291 incidents to
be considered for further analysis.
Substandard medicines
Defects in substandard medicines accounted for the
bulk of these incidents. Two hundred and eighty medi-
cines (96%) were reported to be substandard (ﬁgure 1).
A total of 222 medicines were recalled. The two most
frequent problems, with the substandard medicines,
were packaging and contamination (table 2).
Contamination was a signiﬁcant issue with parenteral
formulations where there were a total of 60 incidents
(see online supplementary table S2). Formulations for
parenteral administration were most frequently affected
by quality issues, with a total of 117 incidents (42%).
Formulations for intravenous administration accounted
for the majority of the cases (89 incidents). Other for-
mulations affected were subcutaneous (15 incidents)
and intramuscular formulations (12 incidents).
Packaging defects were the other most frequent
problem. In many cases these involved signiﬁcant clinical
issues such as incorrect name, strength or active ingredi-
ent of a medicine on the packaging or errors in the
product information leaﬂet in relation to administration
or toxicity. The number of defective medicines was
highest among drugs that act on the nervous system (45/
280), cardiovascular system (41) and infections (35).
When these medicines were classiﬁed by therapeutic
class, those most frequently reported defective were anti-
hypertensives (27/280), antineoplastic agents (21/280)
and antibacterials (19/280). Details are given in online
supplementary table S3.
The UK Health and Social Care Information Centre
published a list of the 20 drugs that contained the great-
est number of items dispensed in 2011 by volume.13 Ten
of these 20 medicines were associated with a total of 22
incidents of substandard medicines.
The study identiﬁed 89 manufacturers, holding the
marketing authorisation for 280 medicines which were
recalled by the MHRA. Manufacturers who held the
marketing authorisation of ﬁve or more recalled medi-
cines are listed in online supplementary table S4.
Fifteen manufacturers ﬁt this criterion. Together, they
hold the authorisation for 163 medicines, accounting
for 58% of all recalled medicines. The majority of these
manufacturers have manufacturing facilities in the UK,
four having headquarters in the UK (Glaxosmithkline,
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AstraZeneca, Martindale Pharmaceuticals and Karib
Kemi Pharm). The online supplementary table S4 also
describes individual manufacturing defects for all listed
manufacturers.
Falsified medicines
Since 2004, 11 incidents of falsiﬁed drugs have been
reported by the MHRA that breached the UK supply
chain (table 3). The last of these was reported in 2009.
In 2007 alone, the MHRA stated in its falsiﬁed medical
products strategy (2012–2015) that more than two
million doses of falsiﬁed medicines entered the supply
chain.10 A total of 7 00 000 doses were recalled from
pharmacies or patients.10 In these alerts, information
regarding the actual problems with the falsiﬁed medi-
cines is given for only 2 of the 11 incidents reported. In
its recent strategy on falsiﬁed medicines, the MHRA
stated that the previous falsiﬁed medicines seized had
Figure 1 Flow diagram of search and resulting alerts and recalls.
Figure 2 Number of drug alerts
and defective medicines reported
in the Medicines and Healthcare
Products Regulatory Agency
alerts from 2001 to 2011.
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Table 1 Substandard medicines recalled by the MHRA under class 1 drug alert
Type of defect Medications Formulation Defect description
Time taken for the MHRA to issue drug
alerts from the first distribution of
defective batches (days)
Substandard medicines
Contamination Zinc oxide BP 15% w/w Local
preparation
Lack of sterility assurance 19
Etoposide 20 mg/mL Injection Lack of sterility assurance Not stated
Paclitaxel 6 mg/mL Injection Lack of sterility assurance Not stated
Tetrofosmin 230 μg Injection Gas filters used in the aseptic manufacturing
process were not sterile
33
Rabies vaccine Injection low level of contamination with live attenuated
rabies virus
64
Nelfinavir mesilate All
presentations
Contaminated originator and parallel distributed
product
Not stated
Major packaging defects Ibuprofen Tablets The product contained rogue quetiapine XL
50 mg tablets and gabapentin 100 mg capsules
117
Ephedrine hydrochloride
3 mg/mL
Injection Ephedrine hydrochloride syringe in a plastic box
erroneously identified as atropine sulfate
injection
44
Bendroflumethiazide
2.5 mg
Tablets This batch contains warfarin 3 mg tablets 210
Delivery issues Temozolomide* Capsules Reports of broken capsules and leakage 38
Temozolomide* Capsules Reports of broken capsules and leakage 91
Fentanyl (40 μg/dose) Transdermal
system
One batch of the transdermal system have been
found to self-activate which has the potential to
cause overdose
Not stated
Salbutamol 100 μg Inhaler Fault with the valve which may lead to higher
doses
120
Potency issues Fentanyl compressed
lozenge
Compressed
lozenge
The potency of the product is out of
specification
242
Issues relating to active
pharmaceutical ingredient
Oxybutynin hydrochloride
5 mg
Tablets Excessive amount of active ingredient 56
Enoxaparin sodium 20
and 40 mg
Injection Excessive amount of active ingredient 207
Other issues Protamine sulfate 10 mg/
mL
Injection Failure of the finished product to meet normal
assay criteria
13
*Two separate incidents.
BP, British pharmacopoeia; MHRA, Medicines and Healthcare Products Regulatory Agency.
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one or more quality defect issues concerning active
ingredients, disintegration, dissolution or presence of
unknown impurities.10
DISCUSSION
This review has shown that the problem of defective
medicines reported in the UK has increased 10-fold over
the 11 years studied. It is likely that the incidence of
defective medicines has actually increased in the UK,
but there is insufﬁcient data to prove this. The most fre-
quent formulations reported to be defective were the
formulations for parenteral administration, which
accounted for 42% of cases. Substandard medicines
represented the bulk of defective medicine incidents,
accounting for over 95% of the cases. Contamination
issues were the most frequently reported clinically rele-
vant problems reported; 80% of these contaminated for-
mulations were formulations for parenteral
administration. There is a greater likelihood of harm to
the patient in association with contaminated parenteral
formulations as highlighted by the recent outbreak of
fungal sepsis in the USA.14 However, these adverse
health consequences have not been documented by the
MHRA or the manufacturers.
Substandard medicines
It is not clear whether the increase in the trend of sub-
standard medicines incidents resulted from new legislation
or strategies by the MHRA, that have made it easier to
detect and report these drugs, or whether the rate of
manufacture of substandard medicines in the UK is
increasing. The overall performance of the MHRA has
improved since it was ofﬁcially launched in 2003.15 16 The
introduction and development of the MHRA’s website
since 2003/2004, as well as the addition of an integrated
site for medicines and medical devices, opened important
communication channels with healthcare providers and
stakeholders.15 The MHRA has introduced guidelines to
healthcare professionals outlining procedures for report-
ing medicines suspected to be defective.8 These guidelines
outline the role that healthcare professionals play in the
initial assessment of suspected defected medicines. They
also illustrate subsequent investigations that can be carried
out by the DMRC before it issues a drug alert. The ease of
access to these guidelines through the MHRA’s website
may increase healthcare providers’ awareness about how
to deal with these drugs. It is now possible to report these
drugs online or over the phone if the healthcare profes-
sional thinks that the defect in a drug may represent a
serious risk to public health.
Table 2 Substandard medicines
Defect type
Number of
medicines
Per
cent Defect details
Number of
medicines
Contamination 74 27 Impurities 44
Lack of sterility assurance 18
Microbial contamination 12
Minor packaging
defects
70 25 Failure to update PIL with administration or safety
warning
40
Incorrect information/description of the dosage form,
strength or dose of a medicine
12
Missing or packing PIL with the wrong carton 6
Others 12
Delivery defects 33 12 Fault with a device 19
Leakage or loose seal 9
Others 5
Major packaging
defects
28 10 Missing or incorrect name ,strength, or active
ingredient of a medicine on carton or box
22
Packing a medicine in the wrong carton 6
Stability defects 23 8 Unspecified stability failure 15
Stability failure of the active ingredient or dissolution
failure prior to expiry
8
Defects in active
ingredient
8 3 Active ingredient is out of specification (either more or
less)
6
Non-homogeneity of the active ingredient in the
formulation
2
Potency 7 2 Subpotent medicine (underlying causes of subpotency
were not stated)
7
Other defects 37 13 GMP deficiencies at manufacturing site or improper
storage of medicines during shipment
23
Others 14
Total 280 100 280
GMP, good manufacturing practice; PIL, patient information leaflet.
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These developments may facilitate the reporting of
defective drugs by healthcare providers or by manufac-
turers. In 2003/2004, the DMRC received 298 reports
about defective medicines.15 The number of these
reports has increased, totalling 830 in 2010/2011.16
However, the level of awareness of healthcare profes-
sionals about these drugs and how to report them has
not been tested. For this reason, the possibility cannot
be excluded that the real incidence as well as the rate of
manufacturing of poor-quality medicines are increasing.
It was of concern that parenteral formulations for intra-
venous injection or infusion where the formulation most
likely to be substandard. The risk of drug toxicity is far
greater with drugs given intravenously than those given
orally. The toxicity associated with substandard medicines
worldwide is unknown.17 Healthcare professionals should
therefore be aware of the expected risk. Healthcare provi-
ders should be educated in the initial assessment of medi-
cines, especially parenteral formulations, for any sign of
impurity, particulate contamination or improper sealing.
If anything appears suspicious, the healthcare providers
should know how to report this defect immediately to the
DMRC before any further harm can occur.
Falsified medicines
The majority of falsiﬁed medicine incidents were
reported by the MHRA in the period between 2004 and
2007. Information regarding the actual quality-defect
type beyond authenticity has been stated for only two
cases. Information on the other nine cases has been
requested from the MHRA but has not been provided.
Five incidents of falsiﬁed drugs were reported in 2007
alone. This led the MHRA to introduce its ﬁrst
anticounterfeiting strategy in 2007.18 The strategy out-
lined a 3-year plan to combat falsiﬁed medicines
through a visionary programme of communication, col-
laboration and regulation. Since then, the MHRA has
reported only one incident in 2009. This may be attribu-
ted to the effectiveness of this strategy in reducing the
availability of these drugs in the UK supply chains.
The UK has a stringent regulatory oversight of the
supply chain, which is represented by the few cases of fal-
siﬁed medicines reported over an 11-year period.
Falsiﬁed medicines are frequently manufactured abroad
and imported to the UK.10 The criminal may choose the
internet for distribution (given that it is less regulated).
Thus, the problem of drug counterfeiting is exacerbated
by unregulated online pharmacies. Patients may use the
internet because of the following: the anonymity of the
internet, offering cheaper medications and receiving pre-
scription—only drugs without prescription.19 Falsiﬁed
drugs do not comply with prerequisite quality and safety
standards and therefore are hazardous to patients’
health, being at best clinically ineffective and at worst can
cause death. The public needs to be made aware of this
risk. Adverse events of these drugs have been reported in
different countries,20 21 including the UK.22
Falsiﬁed medicines are criminal problem according to
the law enforcement agencies and a menace to public
health. Falsiﬁed medicines are more likely if there is a
weak regulatory system and supply chain. In order to
tackle the issue of falsiﬁed medicines, a multisectoral
approach is needed. This needs to involve law enforce-
ment agencies alongside global public health stake-
holders, from public as well as private sectors, and the
media.
Table 3 Drug alerts relating to falsified medicines
Number Medicines Year Formulation Recall level
Stated problem/defect
description
Class of
drug alert
(1–4)
1 Salmeterol 25 μg/fluticasone
propionate 250 μg (seretide
250)
2009 Evohaler Pharmacy and
wholesaler
A reduced patient dose 2
2 Sensodyne original and
sensodyne mint in 50 mL
tubes
2007 Toothpaste Caution Counterfeit toothpaste
contains diethylene glycol
(nephrotoxic and neurotoxic
poison)
4
3 Clopidogrel 75 mg (Plavix)* 2007 Tablets Pharmacy
Not likely to pose an
immediate risk to patients.
(parallel imported product)
1
4 Bicalutamide 50 mg
(Casodex)
2007 Tablets Patient 1
5 Clopidogrel 75 mg (Plavix)* 2007 Tablets Pharmacy 1
6 Olanzapine 10 mg (Zyprexa) 2007 Tablets Patient 1
7 Atorvastatin 20 mg (Lipitor)* 2006 Tablets Pharmacy
)
2
8 Atorvastatin 20 mg (Lipitor)* 2006 Tablets Pharmacy 2
9 Atorvastatin 20 mg (Lipitor) 2005 Tablets Pharmacy 2
10 Sibutramine 15 mg
(Reductil)
2004 Capsules Patient 2
11 Tadalafil 20 mg (Cialis) 2004 Tablets Patient 2
*Separate incidents of the same drug in the same year.
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Pharmacovigilance
Events caused by defective medicines are sometimes
relatively difﬁcult to distinguish from those considered
to be the result of accidents, errors or adverse drug reac-
tions. An example is the fentanyl transdermal patch.
Fentanyl is a strong opioid analgesic (about 80 times
stronger than morphine) used to treat chronic pain.23
It has a narrow therapeutic window, and an overdose
can result in adverse effects, including respiratory arrest
and death. Several deaths due to fentanyl patch over-
dose have been reported worldwide,24 including the
UK.25 Overdoses can be caused by excessive application
of patches, incorrect product use (eg, cutting the patch)
and exposing the patches or the skin to any kind of
heat, which can dramatically increase the drug’s absorp-
tion through the skin.24 Certain fentanyl patches and
transdermal systems have been recalled in different
countries,26 27 including the UK (table 1). The defects
in all cases resulted from either a cut in one side of the
fentanyl patch reservoir or self-activation of the transder-
mal system; both have the potential to cause overdose.
In such cases, it can be difﬁcult to distinguish between
the events related to adverse drug reaction, misuse or
accidents, and those that are caused by defective pro-
ducts. There is a possibility, therefore, that some cases of
adverse events related to this defect have been attributed
to the adverse-reaction nature of the drug and have
gone unreported.
Limitations
The main limitation of the review was the lack of avail-
able data on the adverse events related to defective med-
icines. The data have been not provided to the authors
by the MHRA or the manufacturers. A comparison
between the expected risk and pharmacovigilance data
could not be performed as pharmacovigilance reports in
the UK are held by the MHRA and are not in the public
domain. Thus, the clinical signiﬁcance of the problem is
unknown. Company-led recalls have been posted on the
MHRA website since 2011; information on these recalls
for previous years has not been provided. Owing to the
lack of information made available, we were not able to
determine the reason(s) for the rise in defective
medicines.
CONCLUSION
The reporting of substandard medicines in the UK is on
the rise. There was an increase from 5 incidents in 2001
to 50 in 2011. Parenteral formulations were most likely
to be substandard. There is a greater likelihood of harm
to the patient in association with contaminated paren-
teral formulations, but the clinical signiﬁcance of the
problem is unknown, due to the lack of information
related to their toxicity. Healthcare providers should
know how to assess the quality of medicines, particularly
parenteral formulations for any sign that can be an indi-
cation of contamination and sterility failure.
Contributors TA performed the search, extracted the data and drafted the
paper. HS double-checked the extracted data, conceived the idea and
interpreted the results. IC had the original idea for the study. IC and TA
designed the review and IC critically revised the manuscript and
supervised the study. All authors approved the final version of the
manuscript.
Funding This research received no specific grant from any funding agency in
the public, commercial or not-for-profit sectors.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Extra data can be accessed through the Dryad data
repository at http://datadryad.org/ with the doi:10.5061/dryad.jv3d2.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/3.0/
REFERENCES
1. Bate R, Jensen P, Hess K, et al. Substandard and falsified
anti-tuberculosis drugs: a preliminary field analysis. Int J Tuberc
Lung Dis 2013;17:308–11.
2. Bate R, Coticelli P, Tren R, et al. Antimalarial drug quality in the
most severely malarious parts of Africa—a six country study. PLoS
ONE 2008;3:e2132.
3. Caudron JM, Ford N, Henkens M, et al. Substandard medicines in
resource-poor settings: a problem that can no longer be ignored.
Trop Med Int Health 2008;13:1062–72.
4. Attaran A, Barry D, Basheer S, et al. How to achieve international
action on falsified and substandard medicines. BMJ 2012;345:e7381.
5. European Commission. Policies to Combat Counterfeit Medicines,
Contribution to Impact Assessment—2008, London. http://ec.europa.
eu/health/files/counterf_par_trade/counterfeit-study-main-report_en.
pdf (accessed 30 Jan 2012).
6. Williams A. Europe prepares to battle the counterfeiters. Pharm
Technol Eur 2011;23:9–11.
7. MHRA. Defective Medicines Report Centre (2011). http://www.mhra.
gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/
Medicines/DefectiveMedicinesReportCentre/index.htm (accessed
30 Jan 2012).
8. MHRA. A Guide to Defective Medicinal Products. http://www.mhra.
gov.uk/home/groups/is-lic/documents/publication/con007572.pdf
(accessed 30 Jan 2012).
9. WHO. WHO’s role in the prevention and control of medical products
of compromised quality, safety and efficacy such as substandard/
spurious/falsely-labelled/falsified/counterfeit medical products. 2011.
http://apps.who.int/gb/ssffc/pdf_files/A_SSFFC_WG2_3-en.pdf
(accessed 1 Jun 2012).
10. MHRA. Falsified Medical Products Strategy (2012–2015). http://
www.mhra.gov.uk/home/groups/ei/documents/websiteresources/
con149816.pdf (accessed 15 Oct 2012).
11. WHOCC. ATC Structure and principles. http://www.whocc.no/atc/
structure_and_principles/ (accessed 30 Jan 2012).
12. MHRA. Counterfeit medicine recalls and previously seen counterfeits.
http://www.mhra.gov.uk/Safetyinformation/
Generalsafetyinformationandadvice/Adviceandinformationforcon
sumers/counterfeitmedicinesanddevices/FalsifiedMedicineRecallsand
previouslyseencounterfeits/index.htm (accessed 15 Oct 2012).
13. HSCIC. Prescriptions Dispensed in the Community, Statistics for
England (2001–2011). http://www.hscic.gov.uk/catalogue/PUB06941
(accessed 15 Dec 2012).
14. Davies E. More US citizens die from meningitis as scope of inquiry
widens. BMJ 2012;345:e7095.
15. MHRA Annual Report and Accounts 2003/04. http://www.mhra.gov.
uk/home/groups/comms-ic/documents/websiteresources/con008340.
pdf (accessed 17 Apr 2012).
16. MHRA annual statistics 2010/11. http://www.mhra.gov.uk/home/
groups/comms-ic/documents/websiteresources/con123239.pdf
(accessed 17 Apr 2012).
17. Edwards IR. Fraudulent and substandard medicines. Getting away
with murder? Drug Saf 2011;34:445–8.
8 Almuzaini T, Sammons H, Choonara I. BMJ Open 2013;3:e002924. doi:10.1136/bmjopen-2013-002924
Substandard and falsified medicines recalls in the UK
 group.bmj.com on April 2, 2014 - Published by bmjopen.bmj.comDownloaded from 
18. MHRA. Anti-counterfeiting strategy 2007–2010. http://www.mhra.
gov.uk/home/groups/ei/documents/websiteresources/con2033156.
pdf (accessed 15 Apr 2012).
19. European Alliance for Access to Safe Medicines. The counterfeiting
superhighway. 2008. http://v35.pixelcms.com/ams/assets/
312296678531/455_EAASM_counterfeiting%20report_020608.pdf
(accessed 5 May 2011).
20. Solomon S. BC woman killed by fake drugs bought online: ‘Metal
toxicity’ from counterfeit pills reinforces danger of Internet meds. Nat
Rev Med 2007. http://www.nationalreviewofmedicine.com/issue/
2007/07_30/4_policy_politics_13.html (accessed 15 Dec 2012).
21. Chaubey S, Sangla K, Suthaharan E, et al. Severe hypoglycaemia
associated with ingesting counterfeit medication. Med J Aust
2010;192:716–17.
22. Barber T, Jacyna M. Acute lead intoxication from medications
purchased online presenting with recurrent abdominal pain and
encephalopathy. J R Soc Med 2011;104:120–3.
23. Käferstein H, Sticht G. Comparison of nonradioactive microtiter plate
enzyme immunoassays for the sensitive detection of fentanyl.
Forensic Sci Int 2000;113:353–7.
24. Jumbelic MI. Deaths with transdermal fentanyl patches. Am J
Forensic Med Pathol 2010;31:18–21.
25. MHRA. Fentanyl patches: serious and fatal overdose from dosing
errors, accidental exposure, and inappropriate use. Drug Saf 2008;2.
http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/
CON087796 (acessed 1 May 2011).
26. FDA. Duragesic (fentanyl transdermal system), class 1 recall notice.
2004. http://www.fda.gov/Safety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/ucm166410.htm (accessed
1 May 2011).
27. Product Recalls Australia, fentanyl transdermal patches. 2005. http://
www.recalls.gov.au/content/index.phtml/itemId/954146 (accessed
1 May 2011).
Almuzaini T, Sammons H, Choonara I. BMJ Open 2013;3:e002924. doi:10.1136/bmjopen-2013-002924 9
Substandard and falsified medicines recalls in the UK
 group.bmj.com on April 2, 2014 - Published by bmjopen.bmj.comDownloaded from 
doi: 10.1136/bmjopen-2013-002924
 2013 3: BMJ Open
 
Tariq Almuzaini, Helen Sammons and Imti Choonara
 
2011)−(2001
 UK: a retrospective review of drug alerts
 Substandard and falsified medicines in the
 http://bmjopen.bmj.com/content/3/7/e002924.full.html
Updated information and services can be found at: 
These include:
Data Supplement
 http://bmjopen.bmj.com/content/suppl/2013/07/22/bmjopen-2013-002924.DC1.html
"Supplementary Data"
References
 http://bmjopen.bmj.com/content/3/7/e002924.full.html#ref-list-1
This article cites 11 articles, 3 of which can be accessed free at:
Open Access
non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
terms, provided the original work is properly cited and the use is
work non-commercially, and license their derivative works on different 
license, which permits others to distribute, remix, adapt, build upon this
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) 
This is an Open Access article distributed in accordance with the
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Collections
Topic
 (603 articles)Public health   
 (201 articles)Pharmacology and therapeutics   
 (182 articles)Health policy   
 
Articles on similar topics can be found in the following collections
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on April 2, 2014 - Published by bmjopen.bmj.comDownloaded from 
